Phase 3 trials of aromatase inhibitors for breast cancer prevention: Following in the path of the selective estrogen receptor modulators

Annals of the New York Academy of Sciences

Volumn 1155, Issue , 2009, Pages 141-161

  Dunn, Barbara K ^a   Ryan, Anne ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Arimidex, tamoxifen alone or in combination (ATAC); Aromatase inhibitor (AI); Breast cancer prevention; Contralateral breast cancer (CLBC); Selective estrogen receptor modulator (SERM); Tamoxifen (TAM)

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ESTROGEN RECEPTOR; EXEMESTANE; LETROZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROPIVERINE; RALOXIFENE; ROFECOXIB; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TAMOXIFEN CITRATE;

ADJUVANT THERAPY; ARTHRALGIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER INVASION; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CATARACT; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; FRACTURE; HIGH RISK PATIENT; HOT FLUSH; HUMAN; INTRADUCTAL CARCINOMA; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL PAIN; OSTEOPOROSIS; OVERALL SURVIVAL; POSTMENOPAUSE; RANDOMIZATION; RISK REDUCTION; STROKE; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UTERUS CANCER; VAGINA DISCHARGE;

EID: 61649120368     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.03688.x     Document Type: Conference Paper

References (66)

1. Jemal, A., R. Siegel, E. Ward, et al. 2008. Cancer statistics, 2008. CA Cancer J. Clin. 58 : 71 96.
2. Althuis, M.D., J.H. Fergenbaum, M. Garcia-Closas, et al. 2004. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol. Biomarkers Prev. 13 : 1558 1568.
3. Ravdin, P.M., K.A. Cronin, N. Howlader, et al. 2007. The decrease in breast-cancer incidence in 2003 in the United States. N. Engl. J. Med. 356 : 1670 1674.
4. Rossouw, J.E., G.L. Anderson, R.L. Prentice, et al. 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list-uids=12117397. JAMA 288 : 321 333.
5. Fisher, B., J.P. Costantino, D.L. Wickerham, et al. 1998. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd= Retrieve&db=PubMed&dopt=Citation&list-uids=9747868. J. Natl. Cancer Inst. 90 : 1371 1388.
6. Vogel, V.G., J.P. Costantino, D.L. Wickerham, et al. 2002. The study of tamoxifen and raloxifene: Preliminary enrollment data from a randomized breast cancer risk reduction trial. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd= Retrieve&db=PubMed&dopt=Citation&list-uids=12123540. Clin. Breast Cancer 3 : 153 159.
7. Nayfield, S.G., J.E. Karp, L.G. Ford, et al. 1991. Potential role of tamoxifen in prevention of breast cancer. http://www.ncbi.nlm.nih.gov/entrez/ query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list-uids=1920492. J. Natl. Cancer Inst. 83 : 1450 1459.
8. Prior, P. & J.A. Waterhouse. 1978. Incidence of bilateral tumours in a population-based series of breast-cancer patients. I. Two approaches to an epidemiological analysis. Br. J. Cancer 37 : 620 634.
9. Hankey, B.F., R.E. Curtis, M.D. Naughton, et al. 1983. A retrospective cohort analysis of second breast cancer risk for primary breast cancer patients with an assessment of the effect of radiation therapy. J. Natl. Cancer Inst. 70 : 797 804.
10. Hemminki, K., J. Ji & A. Forsti. 2007. Risks for familial and contralateral breast cancer interact multiplicatively and cause a high risk. Cancer Res. 67 : 868 870.
11. Early Breast Cancer Trialists' Collaborative Group. 1998. Tamoxifen for early breast cancer: An overview of the randomised trials. http://www.ncbi.nlm. nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt= Citation&list-uids=9605801. Lancet 351 : 1451 67.
12. Early Breast Cancer Trialists' Collaborative Group. 2005. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 : 1687 1717.
13. Dunn, B.K. & L.G. Ford. 2001. From adjuvant therapy to breast cancer prevention: BCPT and STAR. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd= Retrieve&db=PubMed&dopt=Citation&list-uids=11469927. Breast J. 7 : 144 157.
14. Arpino, G., H.L. Weiss, G.M. Clark, et al. 2005. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J. Clin. Oncol. 23 : 4687 4694.
15. Kaas, R., J.L. Peterse, A.A. Hart, et al. 2003. The influence of tamoxifen treatment on the oestrogen receptor in metachronous contralateral breast cancer. Br. J. Cancer 88 : 707 710.
16. Powles, T., R. Eeles, S. Ashley, et al. 1998. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd= Retrieve&db=PubMed&dopt=Citation&list-uids=9672274. Lancet 352 : 98 101.
17. Veronesi, U., P. Maisonneuve, A. Costa, et al. 1998. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list-uids=9672273. Lancet 352 : 93 97.
18. Cuzick J., J. Forbes, R. Edwards, et al. 2002. First results from the International Breast Cancer Intervention Study (IBIS-I): A randomised prevention trial. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list-uids=12243915. Lancet 360 : 817 824.
19. Cuzick, J., J.F. Forbes, I. Sestak, et al. 2007. Long-term results of tamoxifen prophylaxis for breast cancer - 96-month follow-up of the randomized IBIS-I trial. J. Natl. Cancer Inst. 99 : 272 282.
20. Cuzick, J., T. Powles, U. Veronesi, et al. 2003. Overview of the main outcomes in breast-cancer prevention trials. http://www.ncbi.nlm.nih.gov/entrez/ query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list-uids=12559863. Lancet 361 : 296 300.
21. Gail, M.H., J.P. Costantino, J. Bryant, et al. 1999. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list-uids=10547390. J. Natl. Cancer Inst. 91 : 1829 1846.
22. Cummings, S.R., S. Eckert, K.A. Krueger, et al. 1999. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list-uids=10376571. JAMA 281 : 2189 2197.
23. Ettinger, B., D.M. Black, B.H. Mitlak, et al. 1999. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. http://www.ncbi.nlm.nih.gov/ entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list-uids= 10517716. JAMA 282 : 637 645.
24. Vogel, V.G., J.P. Costantino, D.L. Wickerham, et al. 2006. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295 : 2727 2741.
25. Gail, M.H., L.A. Brinton, D.P. Byar, et al. 1989. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd= Retrieve&db=PubMed&dopt=Citation&list-uids=2593165. J. Natl. Cancer Inst. 81 : 1879 1886.
26. FDA News. September 14, 2007. http://www.fda.gov/bbs/topics/NEWS/2007/ NEW01698.html, last accessed July 3, 2008.
27. Herold, C.I. & K.L. Blackwell. 2008. Aromatase inhibitors for breast cancer: Proven efficacy across the spectrum of disease. Clin. Breast Cancer 8 : 50 64.
28. Cuzick, J. 2008. Aromatase inhibitors in early breast-cancer treatment: The story so far. Breast 17 (S3 2 8.
29. Baum, M., A. Buzdar, J. Cuzick, et al. 2002. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd= Retrieve&db=PubMed&dopt=Citation&list-uids=12090977. Lancet 359 : 2131 2139.
30. Baum, M., A. Buzdar, J. Cuzick, et al. 2003. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, tamoxifen alone or in combination) trial efficacy and safety update analyses. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list-uids=14584060. Cancer 98 : 1802 1810.
31. Howell, A., J. Cuzick, M. Baum, et al. 2005. Results of the ATAC (Arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. http://www.ncbi.nlm.nih.gov/entrez/ query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list-uids=15639680. Lancet 365 : 60 62.
32. Forbes, J.F., J. Cuzick, A. Buzdar, et al. 2008. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 9 : 45 53.
33. Buzdar, A., A. Howell, J. Cuzick, et al. 2006. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: Long-term safety analysis of the ATAC trial. Lancet Oncol. 7 : 633 43.
34. Jakesz, R., W. Jonat, M. Gnant, et al. 2005. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366 : 455 462.
35. Boccardo, F., A. Rubagotti, M. Puntoni, et al. 2005. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J. Clin. Oncol. 23 : 5138 5147.
36. Jonat, W., M. Gnant, F. Boccardo, et al. 2006. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: A meta-analysis. Lancet Oncol. 7 : 991 996.
37. Cuzick, J. 2003. Aromatase inhibitors in prevention-Data from the ATAC (Arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (The Second International Breast Cancer Intervention Study). http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list-uids=12903846. Recent Results Cancer Res. 163 : 96 103 discussion 264-266.
38. Cuzick, J. 2005. Aromatase inhibitors for breast cancer prevention. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list-uids=15755971. J. Clin. Oncol. 23 : 1636 1643.
39. Cuzick, J. 2008. Chemoprevention of breast cancer. Breast Cancer 15 : 10 16.
40. IBIS-II Study. http://www.ibis-trials.org/index.php, last accessed April 11, 2008.
41. Coombes, R.C., E. Hall, L.J. Gibson, et al. 2004. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd= Retrieve&db=PubMed&dopt=Citation&list-uids=15014181. N. Engl. J. Med. 350 : 1081 1092.
42. Coombes, R.C., L.S. Kilburn, C.F. Snowdon, et al. 2007. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial. Lancet 369 : 559 570.
43. Coleman, R.E., L.M. Banks, S.I. Girgis, et al. 2007. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): A randomised controlled study. Lancet Oncol. 8 : 119 127.
44. Goss, P.E., S. Qi, A.M. Cheung, et al. 2004. Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats. Clin. Cancer Res. 10 : 5717 5723.
45. Goss, P.E., S. Qi, R.G. Josse, et al. 2004. The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats. Bone 34 : 384 392.
46. Goss, P.E., H. Richardson, R. Chlebowski, et al. 2007. National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: Evaluation of exemestane to prevent breast cancer in postmenopausal women. Clin. Breast Cancer 7 : 895 900.
47. Richardson, H., D. Johnston, J. Pater & P. Goss. 2007. The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: An international breast cancer prevention trial. Curr. Oncol. 14 : 89 96.
48. Parrett, M.L., R.E. Harris, F.S. Joarder, et al. 1997. Cyclooxygenase-2 gene expression in human breast cancer. Int. J. Oncol. 10 : 503 507.
49. Hwang, D., D. Scollard, J. Byrne & E. Levine. 1998. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J. Natl. Cancer Inst. 90 : 455 460.
50. Half, E., X.M. Tang, K. Gwyn, et al. 2002. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res. 62 : 1676 1681.
51. Khuder, S.A. & A.B. Mutgi. 2001. Breast cancer and NSAID use: A meta-analysis. Br. J. Cancer 84 : 1188 1192.
52. Bresalier, R.S., R.S. Sandler, H. Quan, et al. 2005. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352 : 1092 102.
53. Phase III Randomized Study of Exemestane in Postmenopausal Women at Increased Risk of Developing Breast Cancer. http://www.cancer.gov/ clinicaltrials/CAN-NCIC-MAP3, last accessed July 5, 2008.
54. Goss, P.E., J.N. Ingle, S. Martino, et al. 2003. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 349 : 1793 1802.
55. Goss, P.E., J.N. Ingle, S. Martino, et al. 2005. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA. 17. J. Natl. Cancer Inst. 97 : 1262 1271.
56. Goss, P.E., J.N. Ingle, J.L. Pater, et al. 2008. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J. Clin. Oncol. 26 : 1948 1955.
57. Thurlimann, B., A. Keshaviah, A.S. Coates, et al. 2005. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353 : 2747 2757.
58. Coates, A.S., A. Keshaviah, B. Thurlimann, et al. 2007. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J. Clin. Oncol. 25 : 486 492.
59. Marshall, E. 2007. Cancer research. Budget pressure puts high-profile study in doubt. Science 315 : 1477.
60. The Lancet. 2007. NCI and the STELLAR trial. Lancet 369 : 2134.
61. The Next Generation of Breast Cancer Prevention: Clinical Trial Background for NSABP P-4. http://www.breastcancerprevention.org/stellar.html, last accessed May 29, 2008.
62. King, M.C., S. Wieand, K. Hale, et al. 2001. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list-uids=11710890. JAMA 286 : 2251 2256.
63. Partridge, A.H., A. LaFountain, E. Mayer, et al. 2008. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J. Clin. Oncol. 26 : 556 562.
64. Donnellan, P.P., S.L. Douglas, D.A. Cameron & R.C. Leonard. 2001. Aromatase inhibitors and arthralgia. J. Clin. Oncol. 19 : 2767.
65. Crew, K.D., H. Greenlee, J. Capodice, et al. 2007. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J. Clin. Oncol. 25 : 3877 3883.
66. Morales, A., S. Pans, K. Verschueren, et al. 2008. Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J. Clin. Oncol. 26 : 1 6.